

**Table 1: The ‘meta-COS’ for research in COVID-19 hospitalised patients**

<b>Scope of the meta COS: Patients being treated in hospital for confirmed or suspected COVID-19</b>				
<b>Outcome domain</b>	<b>WHO COS [3]</b>	<b>Jin et al [4]</b>	<b>Qiu et al [5]</b>	<b>Tong et al [6]</b>
<b>Key stakeholder groups included; geographical location</b>				
	Health professionals, funders, policymakers; International	Health professionals; China	Health professionals, patients, public; China	Health professionals, patients, public; International
<b>Mortality</b>	✓	✓	✓	✓
	Agreed*: All-cause mortality at hospital discharge  Researchers should also consider ‘time to death’, clearly defined as appropriate for their research question.	Agreed*: All-cause mortality at hospital discharge  Researchers should also consider ‘time to death’, clearly defined as appropriate for their research question.	Agreed*: All-cause mortality at hospital discharge  Researchers should also consider ‘time to death’, clearly defined as appropriate for their research question.	Agreed*: All-cause mortality
<b>Respiratory support</b>	✓	✓	✓	✓
	Agreed*: Type of respiratory support, as appropriate to the research question: - oxygen by mask or nasal prongs; - oxygen by NIV or high flow; - intubation & mechanical ventilation; - ECMO.	Agreed*: Type of respiratory support, as appropriate to the research question: - oxygen by mask or nasal prongs; - oxygen by NIV or high flow; - intubation & mechanical ventilation; - ECMO.	Agreed*: Type of respiratory support, as appropriate to the research question: - oxygen by mask or nasal prongs; - oxygen by NIV or high flow; - intubation & mechanical ventilation; - ECMO.	Agreed*: Respiratory failure
* This table was agreed on the 2 <sup>nd</sup> April 2020, and updated on the 15 <sup>th</sup> April, by the following: COS developers - John Marshall (WHO), Junhua Zhang (Tianjin University of Traditional Chinese Medicine), Ruijin Qiu (Beijing University of Chinese Medicine), Bronagh Blackwood (Queen’s University Belfast), Ian Sinha (Alder Hey Children’s Hospital), Allison Tong (University of Sydney) COMET Management Group - Paula Williamson (University of Liverpool), Liz Gargon (University of Liverpool)				

15<sup>th</sup> March 2021

[3] <http://www.comet-initiative.org/Studies/Details/1528>

Lead: John Marshall, University of Toronto, Canada on behalf of the WHO Working Group on the Clinical Characteristics of COVID-19 infection

Summary: WHO has published a master protocol for COVID-19 studies, which recommends the outcomes to be measured in each of these. The WHO Working Group undertook a consensus exercise to agree a COS and the report is now published: [https://doi.org/10.1016/S1473-3099\(20\)30483-7](https://doi.org/10.1016/S1473-3099(20)30483-7)

[4] <http://www.comet-initiative.org/Studies/Details/1523>

Lead: Junhua Zhang, Evidence-Based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin, China

Summary: This COS is published - <https://www.sciencedirect.com/science/article/pii/S2095809920300424?via%3Dihub>

A Case Report Form for this COS has been drafted. Please contact Janneke van't Hooft, [janneke@stanford.edu](mailto:janneke@stanford.edu), to obtain a copy.

[5] <http://www.comet-initiative.org/Studies/Details/1507>

Lead: Ruijin Qiu, Dongzhimen Hospital, Beijing University of Chinese Medicine, China

Summary: This COS is published: <https://www.frontiersin.org/articles/10.3389/fphar.2020.00781/full>

[5] <http://www.comet-initiative.org/Studies/Details/1548>

Lead: Allison Tong, University of Sydney, Australia

Summary: This COS is now published: [https://journals.lww.com/ccmjournal/Fulltext/2020/11000/Core\\_Outcomes\\_Set\\_for\\_Trials\\_in\\_People\\_With.10.aspx](https://journals.lww.com/ccmjournal/Fulltext/2020/11000/Core_Outcomes_Set_for_Trials_in_People_With.10.aspx)

The study has a particular focus on patients, family and community members. You can visit the website for more information about this study: <https://www.covid-19-cos.org>.